Bo Huang

ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 22

Top Venues

Pharmaceutical statistics

Journal of biopharmaceutical statistics

Statistics in medicine

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

University of Wisconsin Madison (PHD)

This page only lists publications with an associated author ORCID identifier.

Education History

University of Wisconsin Madison Jul 15 2003 - Dec 15 2007

United States

PHD :: Statistics

Publications

Peng Yang, Daniel Li, Ruitao Lin, Bo Huang, Ying Yuan
Design and sample size determination for multiple-dose randomized phase II trials for dose optimization. Statistics in medicine (2024)
Peng Yang, Daniel Li, Ruitao Lin, Bo Huang, Ying Yuan
Design and sample size determination for multiple-dose randomized phase II trials for dose optimization. Statistics in medicine 43 (15) (2024)
Peng Yang, Daniel Li, Ruitao Lin, Bo Huang, Ying Yuan
Design and sample size determination for multiple-dose randomized phase II trials for dose optimization. Statistics in medicine 43 (15) (2024)
Thomas Powles, Se Hoon Park, Claudia Caserta, Begoña P Valderrama, Howard Gurney, Anders Ullén, Yohann Loriot, Srikala S Sridhar, Cora N Sternberg, Joaquim Bellmunt, Jeanny B Aragon-Ching, Jing Wang, Bo Huang, Robert J Laliberte, Alessandra di Pietro, Petros D Grivas
Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Duo-Lao Wang, Sirui Zheng, Ying Cui, Nengjie He, Tao Chen, Bo Huang
Adjusted win ratio using the inverse probability of treatment weighting. Journal of biopharmaceutical statistics (2023)
Gaohong Dong, David C Hoaglin, Bo Huang, Ying Cui, Duolao Wang, Yu Cheng, Margaret Gamalo
The stratified win statistics (win ratio, win odds, and net benefit). Pharmaceutical statistics (2023)
Ryan Sun, Bo Huang, Lee-Jen Wei
Comparing Short- and Long-Term Treatment Duration of Bevacizumab for Advanced Ovarian Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
James Song, Johan Verbeeck, Bo Huang, David C Hoaglin, Margaret Gamalo, Yodit Seifu, Duo-Lao Wang, Freda Cooner, Gaohong Dong
The win odds: statistical inference and regression. Journal of biopharmaceutical statistics (2022)
Bo Huang, Lu Tian
Utilizing restricted mean duration of response for efficacy evaluation of cancer treatments. Pharmaceutical statistics 21 (5) (2022)
Ying Cui, Gaohong Dong, Pei Fen Kuan, Bo Huang
Evidence synthesis analysis with prioritized benefit outcomes in oncology clinical trials. Journal of biopharmaceutical statistics (2022)
Gaohong Dong, Bo Huang, Johan Verbeeck, Ying Cui, James Song, Margaret Gamalo, Duolao Wang, David C Hoaglin, Yodit Seifu, Tobias Mütze, John Kolassa
Win statistics (win ratio, win odds, and net benefit) can complement one another to show the strength of the treatment effect on time-to-event outcomes. Pharmaceutical statistics (2022)
Alex F Herrera, Catherine Burton, John Radford, Fiona Miall, William Townsend, Armando Santoro, Pier Luigi Luigi Zinzani, David Lewis, Camilla Fowst, Satjit Brar, Bo Huang, Aron Thall, Graham P Collins
Avelumab in relapsed/refractory classical Hodgkin lymphoma: phase 1b results from the JAVELIN Hodgkins trial. Blood advances 5 (17) (2021)
Mehmet Asim Bilen, Brian I Rini, Martin H Voss, James Larkin, John B A G Haanen, Laurence Albiges, Lance C Pagliaro, Eric G Voog, Elaine T Lam, Nikolay Kislov, Bradley Alexander McGregor, Aly-Khan A Lalani, Bo Huang, Alessandra di Pietro, Stan Krulewicz, Paul B Robbins, Toni K Choueiri
Association of Neutrophil-to-Lymphocyte Ratio With Efficacy of First-Line Avelumab Plus Axitinib vs Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial. Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
Gaohong Dong, L U Mao, Bo Huang, Margaret Gamalo-Siebers, Jiuzhou Wang, GuangLei Yu, David C Hoaglin
The inverse-probability-of-censoring weighting (IPCW) adjusted win ratio statistic: an unbiased estimator in the presence of independent censoring. Journal of biopharmaceutical statistics 30 (5) (2020)
Gaohong Dong, Bo Huang, Duolao Wang, Johan Verbeeck, Jiuzhou Wang, David C Hoaglin
Adjusting win statistics for dependent censoring. Pharmaceutical statistics 20 (3) (2020)
Lu Tian, Hua Jin, Hajime Uno, Ying Lu, Bo Huang, Keaven M Anderson, Lee-Jen Wei
On the empirical choice of the time window for restricted mean survival time. Biometrics 76 (4) (2020)
Bo Huang, Lu Tian, Zachary Ryan McCaw, Xiaodong Luo, Enayet Talukder, Mace Rothenberg, Wanling Xie, Toni K Choueiri, Dae Hyun Kim, Lee-Jen Wei
Analysis of Response Data for Assessing Treatment Effects in Comparative Clinical Studies. Annals of internal medicine 173 (5) (2020)
Ray S Lin, Ji Lin, Satrajit Roychoudhury, Keaven M Anderson, Tianle Hu, Bo Huang, Larry F Leon, Jason J Z Liao, Rong Liu, Xiaodong Luo, Pralay Mukhopadhyay, Rui Qin, Kay Tatsuoka, Xuejing Wang, Yang Wang, Jian Zhu, Tai-Tsang Chen, Renee Iacona, null null
Rejoinder to Letter to the Editor "The Hazards of Period Specific and Weighted Hazard Ratios". Statistics in biopharmaceutical research 12 (4) (2020)
Gaohong Dong, Bo Huang, Yu-Wei Chang, Yodit Seifu, James Song, David C Hoaglin
The win ratio: Impact of censoring and follow-up time and use with nonproportional hazards. Pharmaceutical statistics 19 (3) (2019)
Bo Huang, Enayet Talukder, Lixin Han, Pei-Fen Kuan
Quantitative decision-making in randomized Phase II studies with a time-to-event endpoint. Journal of biopharmaceutical statistics 29 (1) (2018)
Bo Huang, Pei-Fen Kuan
Comparison of the restricted mean survival time with the hazard ratio in superiority trials with a time-to-event end point. Pharmaceutical statistics 17 (3) (2017)
Bo Huang
Some statistical considerations in the clinical development of cancer immunotherapies. Pharmaceutical statistics 17 (1) (2017)

Bo Huang.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Bo Huang